Table 2. Univariate and Multivariate Cox analysis for evaluating RFS.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| FIGO (IIB vs. III+IVA) | 1.675 (1.024, 2.739) | 0.040* | 1.181 (0.688, 2.027) | 0.546 | |
| Tumor diameter | 1.474 (1.173, 1.853) | 0.001* | 1.008 (0.779, 1.303) | 0.954 | |
| Differentiation (well-moderately vs. poor) | 0.898 (0.504, 1.599) | 0.714 | – | – | |
| SMLNs (yes vs. no) | 2.695 (1.625, 4.395) | <0.001** | 2.225 (1.309, 3.782) | 0.003* | |
| SCC-ag (ng/mL) | 1.022 (1.008, 1.035) | 0.001* | 0.996 (0.979, 1.012) | 0.607 | |
| NLR | 1.373 (1.219, 1.546) | <0.001** | 1.195 (1.004, 1.422) | 0.045* | |
| PLR | 1.010 (1.006, 1.014) | <0.001** | 1.004 (0.999, 1.009) | 0.097 | |
| Hb (g/L) | 0.995 (0.984, 1.008) | 0.460 | – | – | |
| MTV-C50% (mL) | 1.088 (1.062, 1.114) | <0.001** | 1.065 (1.033, 1.099) | <0.001** | |
*, indicates a statistical significance with P<0.05; **, represents P<0.001. RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; FIGO, Federation International of Gynecology and Obstetrics; SMLNs, suspicious metastatic lymph nodes; SCC-ag, squamous cell carcinoma antigen; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; Hb, hemoglobin. MTV-C50%: MTV of the combination of the primary tumor and SMLNs estimated by using the 50%SUVmax threshold.